Calprotectin levels predicts relapse in patients with RA, PsA treated with TNF inhibitors

Baseline calprotectin serum levels independently predict disease relapse in patients with rheumatoid arthritis and psoriatic arthritis who have achieved remission or low disease activity, according to findings published in Arthritis Research & Therapy. “Our research group has demonstrated that serum calprotectin stratifies disease activity more accurately than C-reactive protein or the erythrocyte sedimentation rate in patients receiving tumor necrosis factor inhibitors or tocilizumab, and strongly correlates with power Doppler ultrasound synovitis in RA and PsA patients with low